Early research suggests first immunotherapy for mesothelioma on the horizon – Medical Xpress
Early research suggests first immunotherapy for mesothelioma on the horizonMedical XpressEarly findings from an ongoing phase II clinical trial in France, MAPS-2, show that immunotherapy may slow the growth of MPM after relapse. At 12 weeks, cancer had… Continue reading
